Canada National · Market Synthesis
Canada’s dental market runs 2–3 years behind the US in marketing sophistication, under some of the strictest advertising rules outside pharma, and the CDCP has commoditized the "new patient" while leaving high-value treatment acquisition wide open.
This is a synthesis of public market data: Statistics Canada’s Survey of Oral Health Care Providers, IBISWorld, Health Canada’s CDCP reporting, and the provincial dental regulators (CDSA, RCDSO, BCCOHP). It is not a scan of individual advertisers. The live layer, the actual ads running in your city and which ones sustain past a month, is a metro scan we run on request.
Dental offices
Annual market revenue
Behind the US
Practices consulted
Key Findings
What the data says.
- 01
The CDCP (launched 2023, expanded 2025) commoditized the "new patient" segment and compressed margins, shifting the growth opportunity to high-value treatment acquisition. Patients now self-sort into "CDCP" vs "private pay" before they call.
- 02
The market runs 2–3 years behind the US: many practices run Google Ads with no landing page, cannot state a cost-per-booked-patient, and have no CRM beyond their practice-management system.
- 03
Financing is the dominant conversion lever for high-ticket segments: Invisalign ~70% out-of-pocket, cosmetic ~95%, All-on-4 ~90%.
- 04
High-consideration buyers consult 2.4 practices before booking, so the funnel must win the third consult, not the first. Counter-intuitively, 55+ implant/All-on-4 buyers prefer longer 7–10 field diagnostic forms.
- 05
After-hours intent is real and underexploited: 22% of lead form fills land 8pm–midnight, and practices with sub-5-minute auto-response out-close morning-callback practices by 2–3x.
- 06
Sleep apnea is the only segment with a meaningful unaware population (10%) and is under-marketed by generalist practices despite frequent medical-insurance coverage.
Segment Economics
Where the money is.
Weighted case values and consult close rates by high-ticket segment.
| Segment | Avg case value (CAD) | Close | Notes |
|---|---|---|---|
| All-on-4 / full arch | | 15–25% | One closed case can cover months of ad spend. ~90% out-of-pocket. |
| Invisalign / ortho | | 40–50% | ~70% out-of-pocket, so financing is the #1 lever. |
| Single implant | | 45–55% | AB $3,200–$5,000; ON $3,800–$6,500. |
| Cosmetic / veneers | | 30–40% | ~95% out-of-pocket; 6–10 veneer case $10K–$25K. |
| Sleep apnea / TMJ | | 35–45% | Medical insurance covers 50–100% in ~40% of cases. |
| Emergency / pain | | 80–88% | Highest-quality lead source. |
| New patient (general) | | 75% | Commoditized by CDCP. |
Buyer Awareness
Different segments need different messages.
Where buyers sit on the awareness spectrum shapes whether an ad should educate or close. Emergency buyers are ready now; All-on-4 and sleep buyers need the long game.
The Wedges
Structural gaps left open.
The same three infrastructure gaps recur here: the openings this market’s advertising has not closed.
Across every advertiser funnel we tore down, in Calgary and the US metros, not one matched a segment-specific ad to a segment-specific page. In Calgary, the single practice that showed pricing before the form was also the only one still running after 60 days.
Segment-specific funnels
A segment ad deserves a segment page. Winning funnels route Invisalign, implant and cosmetic traffic to purpose-built pages: segment-specific hero, trust signals, and pricing shown before the form, not after. It’s the pattern that correlated with longevity in the scan, and almost no one runs it.
Read the one-star reviews and the pattern repeats: patients describe implants that failed within days, on five-figure bills. The market’s ads act as if that fear doesn’t exist. The scan agrees: most creative still leads with discounts; the ads that last speak to the fear instead.
Sophistication-matched creative: meet the buyer where the fear is
Sophistication stage is the ceiling; fear is the substance. The creative that sustains addresses regret, financing anxiety and provider abandonment, the things patients actually write about, not another “$2,000 off.” In the Calgary sample, 55% of ads were still discount-led; the advertisers that sustained ran mechanism and identity.
In one active engagement, the ads were working. Qualified leads were landing for under $40, but the practice couldn’t see it. The leak was downstream of the click, invisible without stage-level attribution. The owner’s read, “the ads aren’t working,” was the exact inverse of the data.
Per-segment attribution
Most practices can’t tell you their close rate on Invisalign specifically; the CRM tags every lead “new patient.” Wire attribution to the segment (which ad produced which booked case, at what cost) and marketing stops being opinion and becomes arithmetic.
Market Context
The numbers behind the market.
Gross margin, incremental new patient
Mobile share of ad traffic
After-hours form fills (8pm–12am)
Marketing as % of revenue
Meta ad adoption
Regulatory & Compliance
The rules of the road.
- Advertising is provincially regulated and among the most restricted outside pharma. BC (BCCOHP) prohibits testimonials, reviews and embedded review links entirely, the most restrictive in North America.
- Ontario (RCDSO) prohibits superlatives ("best", "state of the art"), incentive programs, and ads that create an "expectation of favourable results". Alberta (CDSA) is moderate: testimonials and before/afters permitted with disclaimer.
- Meta’s Jan 2025 Health & Wellness update restricts lower-funnel conversion events for healthcare advertisers and flags cosmetic before/after photos as potentially generating "negative self-perception".
- No US-style HIPAA equivalent: PIPEDA + provincial privacy law (Alberta PIPA, BC PIPA, Ontario PHIPA) govern patient data, a materially lighter tracking-compliance load than the US.
From National to Local
See these patterns in your own metro.
National intelligence sets the thesis. The live proof is local, so request the scan for your market.